Daan J.A. Crommelin
Utrecht University
BiophysicsVesicleDrug carrierGene deliveryMolecular biologyAntibodyAqueous solutionLiposomeChemistryPolymer chemistryIn vitroIn vivoPhosphatidylcholineImmunogenicityChromatographyBiochemistryMedicineDosage formBiologyPharmacology
385Publications
90H-index
16.7kCitations
Publications 339
Newest
#1Linde Schoenmaker (LEI: Leiden University)H-Index: 1
#2Dominik Witzigmann (UBC: University of British Columbia)H-Index: 20
Last. Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
view all 7 authors...
Abstract A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP product stability. Analysis of mRNA-LNP st...
Source
#1Karin H. Hoogendoorn (LUMC: Leiden University Medical Center)H-Index: 6
#2Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
Last. Wim Jiskoot (LEI: Leiden University)H-Index: 85
view all 3 authors...
Abstract The formulation of cell-based medicinal products (CBMPs) poses major challenges because of their complexity, heterogeneity, interaction with their environment (e.g., the formulation buffer, interfaces), and susceptibility to degradation. These challenges can be quality, safety, and efficacy related. In this commentary we discuss the current status in formulation strategies of off-the-shelf and non-off-the-shelf (patient-specific) CBMPs and highlight advantages and disadvantages of each ...
Source
#1Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
#2Thomas J. Anchordoquy (UM: University of Montana)H-Index: 38
Last. Enrico Mastrobattista (UU: Utrecht University)H-Index: 50
view all 5 authors...
As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain. We then review the literature on the pharmaceutical stability of mRNA vaccine candidates, including attempts to improve their stabili...
Source
#1Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
#2David B. Volkin (KU: University of Kansas)H-Index: 41
Last. Wim Jiskoot (LEI: Leiden University)H-Index: 85
view all 5 authors...
Once Covid-19 vaccines become available, 5-10 billion vaccine doses should be globally distributed, stored and administered. In this commentary, we discuss how this enormous challenge could be addressed for viral vector-based Covid-19 vaccines by learning from the wealth of formulation development experience gained over the years on stability issues related to live attenuated virus vaccines and viral vector vaccines for other diseases. This experience has led -over time- to major improvements on...
Source
#1Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
#2Peter van HoogevestH-Index: 13
Last. Gert Storm (UU: Utrecht University)H-Index: 109
view all 3 authors...
Abstract The rapid rise in interest in ‘nanomedicines’ in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: ‘where to go with nanomedicines’? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved an...
Source
#1Bernard Metz (UU: Utrecht University)H-Index: 17
Last. Wim Jiskoot (LEI: Leiden University)H-Index: 85
view all 10 authors...
Abstract Diphtheria toxoid is produced by detoxification of diphtheria toxin with formaldehyde. This study was performed to elucidate the chemical nature and location of formaldehyde-induced modifications in diphtheria toxoid. Diphtheria toxin was chemically modified using four different reactions with the following reagents: (1) formaldehyde and NaCNBH3, (2) formaldehyde, (3) formaldehyde and NaCNBH3 followed by formaldehyde and glycine, and (4) formaldehyde and glycine. The modifications were ...
Source
#1Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
#2Enrico Mastrobattista (UU: Utrecht University)H-Index: 50
Last. Wim Jiskoot (LEI: Leiden University)H-Index: 85
view all 5 authors...
Abstract In 2003 Crommelin et al. published an article titled: ‘Shifting paradigms: biopharmaceuticals versus low molecular weight drugs’ ( https://doi.org/10.1016/S0378-5173(03)00376-4 ). In the current commentary, 16 years later, we discuss pharmaceutically relevant aspects of the evolution of biologics since then. First, we discuss the increasing repertoire of biologics, in particular the rapidly growing monoclonal antibody family and the advent of advanced therapy medicinal products (ATMPs)....
Source
Source
Last. Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
view all 3 authors...
Source
#1Kevin Klein (UU: Utrecht University)H-Index: 5
#2Pieter Stolk (UU: Utrecht University)H-Index: 14
Last. J.S.B. De VliegerH-Index: 1
view all 6 authors...
Abstract “Non-biological complex drugs” (NBCDs), such as liposomal formulations, iron-carbohydrate complexes and glatiramoids, gained increased interest from a regulatory perspective in recent years. Similar to biologics, the quality of NBCD products is highly dependent on a robust and well-controlled manufacturing process. This provides challenges for generic drug developers to replicate NBCD products once market exclusivity of the originator product is expired. However, unlike biologics for wh...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.